Medical sector’s Albireo Pharma Stock Forecast, Price & News’s (NASDAQ:ALBO) Buy rating Reiterated by Robert W. Baird

Albireo Pharma Stock Forecast, Price & News (NASDAQ:ALBO)‘s stock had its Buy rating Reiterated by analysts at Robert W. Baird in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 596.9M and a beta of 1.42.  Albireo Pharma Stock Forecast, Price & News has a twelve month low $27.23 of  and a twelve month high of $43.41.

Shares of Albireo Pharma Stock Forecast, Price & News traded up $0.68 on Wednesday, reaching $30.89. 208,605 shares of the stock traded hands, compared to its average volume of 153928. Shares of Albireo Pharma Stock Forecast, Price & News at close on Wednesday were at $30.89. The firm’s 50 day moving average is $30.03 and its 200 day moving average is 33.29.Albireo Pharma Stock Forecast, Price & News  has a 12 month low of $30.56 and a 12 month high of $43.41. While on yearly highs and lows, Albireo Pharma Stock Forecast, Price & News’s today has traded high as $31.12 and has touched $30.56 on the downward trend. See More Analyst Rating at: RATING

Albireo Pharma Stock Forecast, Price & News (NASDAQ:ALBO) Moving Average Technical Analysis

5 day Moving Average is 30.38 And 5 day price change is 1.21 (4.09%)  with average volume for 5 day average is 68,463. While technical analysis for average 20 days shows significant difference, 20 day moving average is  30.77 and 20 day price change is 1.16 (3.92%) and average 20 day moving volume is 143,291. 50 day moving average is 30.03  and 50 day price change is 3.23 ( 11.73%)  and with average volume for 50 days is : 155,004. 200 day moving average is 33.29  and 200 day price change is -6.81 (-18.12%)  and with average volume for 200 days is : 191,202.

See More Analyst Rating at: RATING

Albireo Pharma Stock Forecast, Price & News Earnings and What to expect: 

Albireo Pharma last announced its earnings data on August 4th, 2021. The biopharmaceutical company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.92) by $0.02. The business earned $2.43 million during the quarter, compared to the consensus estimate of $2.60 million. Albireo Pharma has generated ($6.73) earnings per share over the last year (($7.45) diluted earnings per share). Earnings for Albireo Pharma are expected to grow in the coming year, from ($6.13) to ($6.10) per share. Albireo Pharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Albireo Pharma are expected to grow in the coming year, from ($6.13) to ($6.10) per share. The P/E ratio of Albireo Pharma is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Albireo Pharma is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Albireo Pharma has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Other owners latest trading in ALBO :

  • On 9/17/2021 shares held by Virtu Financial LLC were 14,969 which equates to market value of $0.53M and appx 0.10% owners of ALBO
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 60,156 which equates to market value of $2.12M and appx 0.00% owners of ALBO
  • On 8/27/2021 shares held by Endurant Capital Management LP were 103,512 which equates to market value of $3.64M and appx 1.00% owners of ALBO
  • In total Institutional ownership equates to Institutional Ownership Percentage: 80.85% for ALBO

See More Analyst Rating at: RATING